The world’s most commonly used Type 2 diabetes drug, Metformin, may be ‘repurposed’ to treat non-diabetic conditions according to researchers from the University of Dundee.

The international study led by Professor Chim Lang and Dr Graham Rena at the Division of Molecular and Clinical Medicine at Dundee suggests that there is now strong evidence that the drug exhibits an anti-inflammatory action which may prove significant in non-diabetic cardiovascular disease.

Inflammation is understood to contribute to cardiovascular disease (CVD) but existing nonsteroidal anti-inflammatory drugs (NSAIDs) have shown limited utility in CVD treatment. …